Extensive‐stage small‐cell lung cancer: Current management and future directions
Extensive‐stage small‐cell lung cancer: Current management and future directions
复制标题
DOI：
10.1002/ijc.34346
复制
发表时间：
2022
期刊：
影响因子：
--
通讯作者：
Yun Fan
中科院分区：
文献类型：
--
作者：
Ying Yu;Kaiyan Chen;Yun Fan
Extensive-stage small-cell lung cancer (ES-SCLC) is regarded as a refractory carcinoma associated with extremely rapid disease progression. After more than three decades without clinical advances, research on immune checkpoint inhibitors (ICIs) combined with platinum-based chemotherapy has led to the first treatment breakthrough, establishing a new standard for the first-line treatment of ES-SCLC. Further studies have extensively evaluated small-molecule antiangiogenic drugs, PARP inhibitors, as well as lurbinectedin in SCLC and have demonstrated some benefit, although no breakthroughs have been made. In addition, newer therapeutic strategies with targeted agents, novel chemotherapeutics and immunotherapies are evolving as they are being actively explored and hold promise for patients with this disease. Notably, the preliminary identification of SCLC molecular subtypes driven by the expression of dominant transcription factors with RNA sequencing profiles has made it possible to identify molecularly tailored therapeutic approaches, which increases the potential for individualized precision treatment of SCLC. In this review, we summarize recent research advances in ES-SCLC, outline the current management of this disease and reflect on directions for future development. This article is protected by copyright. All rights reserved.
